The latest price target for Royalty Pharma (NASDAQ:RPRX) was reported by TD Cowen on December 11, 2025. The analyst firm set a price target for $45.00 expecting RPRX to rise to within 12 months (a possible 15.80% upside). 5 analyst firms have reported ratings in the last year.

The latest analyst rating for Royalty Pharma (NASDAQ:RPRX) was provided by TD Cowen, and Royalty Pharma maintained their buy rating.

There is no last upgrade for Royalty Pharma

The last downgrade for Royalty Pharma PLC happened on June 3, 2024 when UBS changed their price target from N/A to $28 for Royalty Pharma PLC.

Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Royalty Pharma, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Royalty Pharma was filed on December 11, 2025 so you should expect the next rating to be made available sometime around December 11, 2026.

While ratings are subjective and will change, the latest Royalty Pharma (RPRX) rating was a maintained with a price target of $42.00 to $45.00. The current price Royalty Pharma (RPRX) is trading at is $38.86, which is out of the analyst’s predicted range.